DHA-clozapine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Template:Short description Template:Drugbox

DHA-clozapine (tentative trade name Clozaprexin)[1] is an atypical antipsychotic drug candidate that was created and originally tested by chemists at Protarga, a small pharmaceutical in Pennsylvania, and scientists at Harvard University.[2]

It is a prodrug of clozapine; the fatty acid docosahexaenoic acid (DHA) was added to clozapine in order to increase penetration of the blood–brain barrier.[3]

Protarga was purchased by Luitpold Pharmaceuticals in 2003 and development was discontinued in 2007.[1]

References

<templatestyles src="Reflist/styles.css" />

  1. a b Script error: No such module "citation/CS1".
  2. Script error: No such module "Citation/CS1".
  3. Script error: No such module "Citation/CS1".

Script error: No such module "Check for unknown parameters".

Script error: No such module "Navbox".

Template:Adrenergic receptor modulators Template:Dopamine receptor modulators Template:Histamine receptor modulators Template:Muscarinic acetylcholine receptor modulators Template:Serotonin receptor modulators Template:Piperazines Template:Tricyclics

Template:Nervous-system-drug-stub